Agenus | Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 43.29B 3.9B 2025-12
Agenus USD 287.13M 52.57M 2025-09
Amgen USD 25.49B 3.7B 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Celldex Therapeutics USD 50.99M 4.53M 2025-12
CSL USD 4.61B 207M 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
Glaxosmithkline GBP 28.68B 8.3B 2025-09
Incyte USD 1.52B 176.44M 2025-12
Intrexon USD 23.02M 38K 2024-06
J&J USD 54.13B 3.26B 2025-12
Jiangsu Hengrui CNY 7.85B 4.39B 2025-09
Karyopharm Therapeutics USD 87.16M 12.06M 2025-09
MacroGenics USD 44.47M 5.47M 2025-09
Merck EUR 8.64B 1.22B 2025-09
Merck USD 28.63B 2.59B 2025-09
Northwest Biotherapeutics USD 87.9M 3.98M 2025-09
Novartis USD 32B 286M 2025-09
Novavax USD 429.87M 40.73M 2025-09
Pfizer USD 36.6B 1.13B 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Veracyte USD 59.94M 12.22M 2025-12


Agenus Passivo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Mar 2026.